Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 623-629

  Kashuba, Angela D M ^a,d   Nafziger, Anne N ^a,b   Drusano, George L ^c   Bertino Jr , Joseph S ^a,b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b BASSETT HEALTHCARE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CREATININE; GENTAMICIN; TOBRAMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GRAM NEGATIVE INFECTION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PNEUMONIA; PRIORITY JOURNAL;

EID: 0032979927     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.623     Document Type: Article

References (35)

1. American Thoracic Society. 1995. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement. Am. J. Respir. Crit. Care Med. 153:1711-1725.
2. Bendush. C. L., S. L. Senior, and H. O. Wooller. 1977 Evaluation of nephrotoxic and ototoxic effects of tobramycin in worldwide study. Med. J. Aust. Spec. Suppl. 2:22-26.
3. Bertino, J. S., Jr., L. A. Booker, P. A. Franck, P. L. Jenkins, K. R. Franck, and A. N. Nafziger. 1993. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect. Dis. 167:173-179.
4. Bertino, J. S., Jr., L. A. Booker, P. Franck, and B. Rybicki. 1991. Gentamicin pharmacokinetics in patients with malignancies. Antimicrob. Agents Chemother. 35:1501-1503.
5. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987 Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic pharmacokinetic concentrations to MIC for bacterial activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1055-1060.
6. Bryan, C. S., and K. L. Reynolds. 1984. Bacteremic nosocomial pneumonia. Am. Rev. Respir. Dis. 129:668-671.
7. Center for Disease Control and Prevention. 1994. National nosocomial infection surveillance study. Hospital Infections Program, Centers for Disease Control and Prevention. Atlanta, Ga.
8. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
9. Collins, T., and D. N. Gerding. 1991. Aminoglycosides versus β-lactams in gram-negative pneumonia. Semin. Respir. Infect. 6(3):136-146.
10. Craven, D. E., K. A. Steeger, and T. W. Barber. 1991. Preventing nosocomial pneumonia: state of the art and perspectives for the 1990's. Am. J. Med. 91:44S-53S.
11. Deziel-Evans, L. M., J. E. Murphy, and M. L. Job. 1986. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin. Pharm. 5:319-324.
12. Donowitz, G. R., and G. L. Mandell. 1995. Acute pneumonia. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y.
13. Fagon, J. Y., Y. Chastre, Y. Domart, J. L. Trouillet, J. Pierre, C. Carne, and C. Gibert. 1989. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Am. Rev. Respir. Dis. 139:877-884.
14. Fagon, J. Y., J. Chastre, A. Hance, P. Montravers, A. Novara, and C. Gibert. 1993. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am. J. Med. 94:281-288.
15. Freeman, J., B. A. Rosner, and J. E. McGowan, Jr. 1979. Adverse effects of nosocomial infection. J. Infect. Dis. 140:732-740.
16. Goss, T. F., A. Forrest, D. E. Nix, C. H. Ballow, M. C. Birmingham, T. J. Cumbo, and J. J. Schentag. 1994. Mathematical examination of dual individualization principles. II. The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann. Pharmacother. 28:863-868.
17. Grant, J. P. 1980. Handbook of total parenteral nutrition. The W. B. Saunders Co., Philadelphia, Pa.
18. Gross, P. A., H. C. New, P. Aswapokee, C. Van Antwerpen, and N. Aswapokee. 1980. Deaths from nosocomial infections: experience in a university hospital and a community hospital. Am. J. Med. 68:219-223.
19. Gross, P. A., and C. Van Antwerpen. 1983. Nosocomial infections and hospital deaths: a case-control study. Am. J. Med. 75:658-662.
20. Jackson, G. G., and L. J. Riff. 1971. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J. Infect. Dis. 124(Suppl.):S185-S191.
21. Kashuba, A. D. M., J. S. Bertino, Jr., and A. N. Nafziger. 1998. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob. Agents Chemother. 42:1842-1844.
22. Klastersky, J., D. Daneau, G. Swings, and D. Weerts. 1974. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J. Infect. Dis. 129:187-193.
23. McCabe, W. R., and G. G. Jackson. 1962. Gram-negative bacteremia. I. Etiology and ecology. Arch. Intern. Med. 110:83-91.
24. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
25. Moore, R. D., C. R. Smith, and P. S. Lietman. 1984. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am. J. Med. 77:657-662.
26. Moore, R. D., C. R. Smith, and P. S. Lietman. 1984. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J. Infect. Dis. 149:443-448.
27. Moore, R. D., C. R. Smith, and P. S. Lietman. 1984. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J. Infect. Dis. 149:23-30.
28. Moore, R. D., C. R. Smith, J. J. Lipsky, E. D. Mellits, and P. S. Lietman. 1984. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann. Intern. Med. 100:352-357.
29. Noone, P., T. M. C. Parsons, J. R. Pattison, R. C. B. Slack, D. Garfield-Davies, and K. Hughes. 1974. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br. Med. J. 1:477-481.
30. SAS Institute. 1985. SAS user's guide. Statistics. SAS Institute, Cary, N.C.
31. Sawchuk, R. J., and D. E. Zaske. 1976. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J. Pharmacokinet. Biopharm. 4:183-195.
32. Sawyers, C. L., R. D. Moore, S. A. Lerner, and C. R. Smith. 1986. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J. Infect. Dis. 33:1062-1068.
33. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles. 1. relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann. Pharmacother. 25:1050-1057.
34. Steinberg, D., and P. Colla. 1995. CART: tree-structured nonparametric data analysis. Salford Systems. San Diego. Calif.
35. Zaske, D. E., J. L. Boatman, L. B. Solem, and R. G. Strate. 1982. Increased burn patient survival with individualized dosages of gentamicin. Surgery 91:142-149.